Compare SPIR & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPIR | AURA |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.1M | 396.8M |
| IPO Year | N/A | 2021 |
| Metric | SPIR | AURA |
|---|---|---|
| Price | $7.30 | $5.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.33 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 614.2K | 188.7K |
| Earning Date | 12-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $77,387,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.92 | N/A |
| P/E Ratio | $8.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.60 | $4.35 |
| 52 Week High | $21.43 | $8.89 |
| Indicator | SPIR | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 41.79 |
| Support Level | $6.60 | $6.27 |
| Resistance Level | $10.19 | $6.69 |
| Average True Range (ATR) | 0.62 | 0.29 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 20.06 | 5.99 |
Spire Global Inc is a provider of space-based data, analytics, and Space Services, offering datasets and powerful insights about Earth from the ultimate vantage point of space so that organizations can make decisions with confidence, accuracy, and speed. It generates revenue from four solutions: Maritime, Aviation, Weather, and Space Services. It offers the following three data solutions to customers; Maritime-precise space-based data used for accurate ship monitoring, ship safety, and route optimization, Aviation-precise space-based data used for accurate aircraft monitoring, aircraft safety, and route optimization, and Weather-precise space-based data used for accurate weather forecasting.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.